ArticleInfectious diseases and therapy2016
Medium- to Long-Term Impact of Rotavirus Vaccination on Hospital Care in Belgium: A 7-Year Follow-Up of the Rotavirus Belgium Impact Study (RotaBIS).
Article in Infectious diseases and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01563146 (Assessing the Number of Rotavirus Related Hospitalizations in 11 Hospitals in Belgium - Season 2006-2007), which is not on this map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Assessing the Number of Rotavirus Related Hospitalizations in 11 Hospitals in Belgium - Season 2006-2007
Who cites it
21 citing papers in PubMed.
- Measuring the Vaccine Success Index: A Framework for Long-Term Economic Evaluation and Monitoring in the Case of Rotavirus Vaccination.Vaccines · 2024Article
- The Economic Value of Rotavirus Vaccination When Optimally Implemented in a High-Income Country.Vaccines · 2023Article
- Established and new rotavirus vaccines: a comprehensive review for healthcare professionals.Human vaccines & immunotherapeutics · 2022Review
- Rotavirus Disease and Genotype Diversity in Older Children and Adults in Australia.The Journal of infectious diseases · 2022Article
- Defining the Recipe for an Optimal Rotavirus Vaccine Introduction in a High-Income Country in Europe.Viruses · 2022Article
- Informing decision makers seeking to improve vaccination programs: case-study Serbia.Journal of market access & health policy · 2021Article
- Lessons Learned from Long-Term Assessment of Rotavirus Vaccination in a High-Income Country: The Case of the Rotavirus Vaccine Belgium Impact Study (RotaBIS).Infectious diseases and therapy · 2020Article
- Rotavirus vaccination for all children or subgroups only? Comment of the European Academy of Paediatrics (EAP) and the European Society for Paediatric Infectious Diseases (ESPID) recommendation group for rotavirus vaccination.European journal of pediatrics · 2020Article
- Article
- Immunogenicity and safety of porcine circovirus-free human rotavirus vaccine in healthy infants: a phase III, randomized trial.The Journal of infectious diseases · 2020Article
- Quantitative Benefit-Risk Models Used for Rotavirus Vaccination: A Systematic Review.Open forum infectious diseases · 2020Review
- How to assess for the full economic value of vaccines? From past to present, drawing lessons for the future.Journal of market access & health policy · 2020Review
- TIPICO IX: report of the 9Human vaccines & immunotherapeutics · 2019Article
- Sustained impact of rotavirus vaccine on rotavirus hospitalisations in Lusaka, Zambia, 2009-2016.Vaccine · 2018Article
- A decade of experience with rotavirus vaccination in the United States - vaccine uptake, effectiveness, and impact.Expert review of vaccines · 2018Review
- Benefit Versus Risk Assessment of Rotavirus Vaccination in France: A Simulation and Modeling Analysis.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2018Article
- Improving the Hospital Quality of Care during Winter Periods by Optimizing Budget Allocation Between Rotavirus Vaccination and Bed Expansion.Applied health economics and health policy · 2018Article
- 3. How comprehensive can we be in the economic assessment of vaccines?Journal of market access & health policy · 2017Review
- 2. How is the economic assessment of vaccines performed today?Journal of market access & health policy · 2017Review
- The Sustained Rotavirus Vaccination Impact on Nosocomial Infection, Duration of Hospital Stay, and Age: The RotaBIS Study (2005-2012).Infectious diseases and therapy · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRotavirus (RV) vaccination was introduced in Belgium in 2006. With the high uptake it had (>85%), a sharp decline in hospitalizations was observed during the first years after vaccine introduction. The objective of this study was to investigate whether this decline was maintained and to simulate projections.
methodsThe Rotavirus Belgium Impact Study allowed an analysis of the RV vaccine impact amongst children in 11 hospitals in Belgium over a 9-year period (2005-2013) with 2 years pre- and 7 years post-vaccine introduction. Results were compared by year and by subsequent birth cohort aging up to 5 years. The two different analysis methods helped dismantling the different (direct and indirect) effects of vaccine protection to simulate future hospitalization trends.
resultsDuring the whole observation period, 40,552 RV detection tests were performed of which 5832 were positive (14.4%). After RV vaccine introduction, a significant reduction in number of tests performed (-38%) was combined with a dramatic drop in numbers of positive tests (-76.6%). The decreases were spectacular during the first two years of vaccine introduction; after that period, the decrease flattened. Cross-sectional comparison with cohort data showed that the initial drop was heavily influenced by the herd effect of the vaccine. Cohort analysis demonstrated a low rate of residual disease over time, suggesting another infection source other than the child population.
conclusionThe residual disease will be maintained in the community when a same vaccination strategy is continued over time, starting vaccination of children only at 6 weeks' time.
fundingGlaxoSmithKline Biologicals SA.
trial registrationClinicalTrials.gov identifier, NCT01563146.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.